

Involvement of the WNT and FGF signaling pathways in non-isolated anorectal malformations: Sequencing analysis of *WNT3A*, *WNT5A*, *WNT11*, *DACT1*, *FGF10*, *FGFR2* and the *T* gene

MARKUS DRAAKEN^{1,2*}, WIEBKE PRINS^{3*}, CLAUDIA ZEIDLER^{3*}, ALINA HILGER¹, SADAF S. MUGHAL¹, JEANETTE LATUS³, THOMAS M. BOEMERS⁴, DOMINIK SCHMIDT^{1,5}, EBERHARD SCHMIEDEKE^{1,6}, NICOLE SPYCHALSKI⁷, ENRIKA BARTELS¹, MARKUS M. NÖTHEN^{1,2}, HEIKO REUTTER^{1,8} and MICHAEL LUDWIG³

¹Institute of Human Genetics, ²Department of Genomics, Life and Brain Center and ³Department of Clinical Chemistry and Clinical Pharmacology, University Hospital of Bonn, D-53127 Bonn; ⁴Department of Pediatric Surgery and Pediatric Urology, Children's Hospital, D-50735 Köln; ⁵Department of Pediatric Surgery, Campus Virchow Clinic, Charité University Hospital Berlin, D-13353 Berlin; ⁶Department of Pediatric Surgery and Urology, Center for Child and Adolescent Health, Hospital Bremen-Mitte, D-28205 Bremen; ⁷Department of Pediatric Surgery, Cnopf'sche Kinderklinik, D-90419 Nürnberg; ⁸Department of Neonatology, Children's Hospital, University Hospital of Bonn, D-53127 Bonn, Germany

Received July 23, 2012; Accepted August 7, 2012

DOI: 10.3892/ijmm.2012.1124

Abstract. Anorectal malformations (ARMs) comprise a broad spectrum of anomalies, including anal atresia, congenital anal fistula and persistence of the cloaca. Research suggests that genetic factors play an important role in ARM development. However, few genetic variants have been identified. Embryogenesis is orchestrated by crosstalk of the wingless-type MMTV integration site family (WNT) and fibroblast growth factor (FGF) signaling pathways in a process that involves several intracellular cascades. Studies in mice have implicated several genes from these pathways in the etiology of ARMs. We performed sequencing analysis of seven of these previously reported genes in 78 patients with ARMs occurring within the context of at least one additional congenital anomaly. No associations were identified with variants in *WNT3A*, *WNT5A*, *WNT11*, *DACT1*, *FGF10* or the *T* gene. In the *FGFR2* gene, three novel heterozygous nucleotide substitutions were identified. Further investigations, including the study of family members, revealed that these variants were not causally related to the phenotype in the present

ARM cohort. Mutations in the seven investigated genes may nonetheless be a cause of ARMs in rare cases. However, further studies should consider genes encoding other proteins in the WNT/FGF signaling pathways as possible candidates.

Introduction

Anorectal malformations (ARMs) comprise a broad spectrum of anomalies including anal atresia, congenital anal fistula and persistence of the cloaca. The estimated incidence of ARMs is approximately 1 in 2,500 to 3,000 live births (1-5) and a male to female ratio of 1.7 has been reported for isolated (non-syndromic) forms (6). Isolated forms account for 40-50% of all ARM cases, and these are sometimes associated with other developmental anomalies, such as renal and urogenital malformations (5,6). In the remaining cases, ARMs occur within the context of defined genetic syndromes or multiple congenital anomalies.

Research suggests that ARMs have a heterogeneous etiology and include Mendelian and multifactorial forms. The latter probably arise as a result of a complex interplay between genetic risk variants and environmental factors. Possible maternal risk factors include use of multivitamins or medications for severe chronic dyspepsia and asthma during pregnancy (7,8), periconceptional injuries or pyrexia, obesity and diabetes. Research also suggests that smoking and certain occupational exposures in either parent may be associated with a higher risk of ARMs (9-12).

Although mutations for some ARM-related syndromes have been identified, the majority of the underlying genetic factors for ARMs remain unknown (13,14). Previously reported genetic factors include the homeobox gene *MNX1* in Currarino syndrome (15), the *SALL1* zinc-finger protein in

Correspondence to: Professor Michael Ludwig, Department of Clinical Chemistry and Clinical Pharmacology, University Hospital of Bonn, 25 Sigmund Freud street, D-53127 Bonn, Germany
E-mail: mludwig@uni-bonn.de

*Contributed equally

Key words: anorectal malformation, brachyury, candidate genes, dapper homolog 1, fibroblast growth factor, fibroblast growth factor receptor, wingless-type MMTV integration site family




Figure 1. Molecular FGF/WNT signaling factor pathways as candidates for ARM. Selected proteins and interactions are shown. FGF signal transduction (binding of FGF10 to its receptor FGFR2) is shown. Formation of the FGF:FGFR:HSPG (heparan sulfate proteoglycans) signaling complex activates extracellular signal-regulated kinases (ERK)/mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K). PI3K activates protein kinase AKT or protein kinase B (PKB), with subsequent inhibition of glycogen synthase kinase 3 β (GSK3 β) by phosphorylation. MAPK dependent phosphorylation of transcription factors allows transcription of FGF target genes. In addition, phosphorylation may promote the release of transcriptional repressor Groucho from transcription factor (TCF) 1. This allows interaction between TCF/lymphoid enhancer-binding factor 1 (LEF1) and β -catenin (β CN) and stimulation of the transcription of WNT-dependent genes, e.g. the *T*-gene (brachyury). In the absence of nuclear β CN, TCF1/LEF1 act as transcriptional repressors by binding to Groucho. β CN can also displace Groucho from TCF1/LEF1. Stabilization of β CN is the major effect of WNT signaling. Absence of this effect leads to phosphorylation of β CN via a destruction complex including axin, the APC gene (mutant in adenomatous polyposis) product and GSK3 β . This mechanism primes β CN-Pi for degradation by the ubiquitin pathway. WNT ligands include the Frizzled (FZD) family of receptors and these signal through co-receptors such as low-density lipoprotein receptor related protein 5/6 (LRP5/6) and the orphan tyrosine kinase receptors ROR1 and ROR2. Binding of WNT3A (inhibited by WNT5A) to a receptor from the Frizzled (FZD) family leads to the activation of Dishellved (DSH), a core component of WNT signaling, thereby enhancing the phosphorylation and subsequent inhibition of GSK3 β . In addition to FZD receptors, WNT5A can also bind and activate ROR2, resulting in the activation of the actin-binding protein filamin A and the JNK signaling pathway. WNT3A and WNT5A exert reciprocal pathway inhibition. WNT11 binds to several FZD (type 4, 5 and 7) receptors. Inhibition of WNT/ β CN signaling may be mediated by competition for FZD receptors. DACT1 can bind β CN and this complex then inhibits GSK3 β . This inhibition represses the destruction complex and leads to the release of β CN, thereby increasing its nuclear and cytoplasmic fraction. The figure is adapted from previous studies (31,60-62).

Townes-Brocks syndrome (16) and the *GLI3* gene in Pallister-Hall syndrome (17).


Since many ARM phenotypes are negatively associated with reproductive fitness, it is reasonable to assume that a substantial proportion of ARM patients carry *de novo* mutations. Thus candidate gene sequencing to identify rare, high-penetrance mutations is a rational approach.

The processes of urogenital and anorectal embryogenesis involves the wingless-type MMTV integration site family (WNT)/fibroblast growth factor (FGF) signaling pathways. Mammalian WNT proteins constitute a family of roughly 20 secreted glycoproteins (18), which act as short-range paracrine signaling effectors. The FGF family comprises 22 extracellular ligands, whose signals are mediated through a family of tyrosine kinase receptors. These are termed the five FGF receptors (FGFR1-5) (19). Alternative splicing generates multiple isoforms for each FGFR. Each isoform is characterized by a differing affinity for the respective ligand (20).

Multiple lines of evidence from mouse models suggest that genes in these signaling pathways (Fig. 1) are implicated in the etiology of ARMs. Mice that are homozygous for a

hypomorphic *Wnt3a* allele display vertebral defects, a short tail due to loss of caudal vertebrae, deficient cloacal development and incomplete uro-rectal septation (21). Moreover, studies involving human pluripotent stem cells have shown that WNT3A is required for hindgut specification (22). *Wnt5a* is expressed in the embryonic colon and rectum and affects the development of the proximal cloacal plate (23). *Wnt5a*-knockout mice display ARMs such as imperforate anus and the presence of fistulas between the urinary and intestinal tracts (24). As with *Wnt3a* and *Wnt5a*, *Wnt11* has been identified in the developing mouse urogenital tract (25). Two studies have reported expression of human WNT11 in the embryonic uro-rectal septum, the urogenital folds, the labioscrotal swellings and the epithelium of the esophagus and colon (26,27). Studies in Chinese hamster ovary cells have shown that *Wnt11* signaling leads to downregulation of the key signaling pathways Wnt/ β -catenin, JNK/AP-1 and NF- κ B (28).

Dapper homolog 1 (*Dact1*) also functions as a negative regulator of Wnt signaling (29), and its inactivation leads to perinatal lethality in *Dact1*^{-/-} mice. Wen *et al* (30)



To explore the possible involvement of the above genes in the etiology of human ARMs, we performed sequencing analysis in a sample of 78 patients with ARMs occurring within the context of multiple congenital anomalies.

Gene analysis. Standard procedures were used for the isolation of genomic DNA, amplification of DNA via polymerase chain reaction (PCR) and performance of the automated sequencing analyses. In brief, primers (sequences available on request) were directed to all exons of the genes *WNT3A*, *WNT5A*, *WNT11*, *DACT1*, *FGF10*, *FGFR2* and *T* (GenBank acc. nos.: NM_033131.3, NM_001256105.1, NM_004626.2, NM_016651.5, NM_004465.1, NM_000141.4, NM_001144913.1-001144919.1, NM_022970.3 and NM_003181.2). The resultant PCR products were subjected to direct automated sequencing (3130xl Genetic Analyzer; Applied Biosystems, Foster City, CA, USA). For each patient,

both strands of each amplicon were sequenced. All nucleotide variations were confirmed via the performance of independent PCR reactions. Segregation of these variants in family members was investigated by sequencing the respective PCR products. In the course of direct sequencing, information was obtained concerning various single nucleotide polymorphisms (SNPs) in the analyzed genes.

RNA analysis. RNA analyses were performed to determine the effect of the DNA variation observed in index patient (case B10) and his mother. The respective blood samples were collected in PAXgene tubes (PreAnalytiX, Hombrechtikon, Switzerland) in order to stabilize the intracellular RNA. RNA for reverse transcription (RT) PCR was prepared with the RNeasy Plus Micro kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions. Primers were directed to *FGFR2* exons 10/11 (10/11F-cDNA: 5'-GACAGTTCTGCCAGCGCCTG-3') and 13 (13R-cDNA: 5'-GCCTCCTTGGGCTTGTCTTTG-3'). This allowed analysis of the effect of the c.G2012A (p.Thr454=) variant (numbering according to GenBank acc. no. NM_022970.3 and Swiss-Prot entry P21802) and detection of alternatively spliced mRNAs.

Results

In our candidate gene approach no variant of likely causal relevance was detected in the genes encoding WNT3A, WNT5A, WNT11, DACT1, FGF10 and T protein. Sequencing analysis of the *FGFR2* gene revealed the presence of novel heterozygous variants in three patients (Fig. 2). These variants are listed neither in the current SNP database (dbSNP136) nor in the 1,000 Genomes catalog.

A synonymous p.Thr454= variant (c.G2012A transition in exon 12) was identified in patient B10 and his mother. Patient B10 presented with anal atresia with fistula, hypospadias, left renal agenesis, rib and vertebral column malformations, lumbar spina bifida occulta and hexadactyly of the right foot. Interestingly, his mother also had spina bifida occulta. A closer look at the sequence surroundings affected by this silent substitution, revealed the formation of a potential novel 3' acceptor splice site in exon 12. Calculation of the consensus value (CV) for splice site recognition (48) revealed a CV of 0.913 for the wild-type sequence (5'-cattttgtatccag^AG; exonic base in capital letter) and a CV of 0.917 for the novel variant (5'-cctctcttcaacag^AC; substitution underlined). The finding of nearly identical CVs suggested an alternative usage of these splice sites with the possible consequence of a deletion of 76 bp (p.Ala455GlnfsX26). Therefore, RNA analysis was performed. However, no novel 425-bp fragment (normal, 501 bp) was detected in the RT-PCR experiments (data not shown). The only detected variation was due to alternative splicing at the exon 11 donor splice site, which has been shown to account for the absence of residues Val428 and Thr429 in several *FGFR2* isoforms (see Swiss-Prot entry P21802).

Another heterozygous exon 12 *FGFR2* variant (c.C2032T) was detected in patient G10. This variant is predicted to result in a p.Ala461Val amino acid substitution. Patient G10 presented with perineal fistula, hypoplasia of the left thumb, pre-axial polydactyly of the left hand, wedged vertebra

(thoracic and cervical), rib malformations, dextroversion cordis and double kidney (left). The mother showed wild-type sequence only, and no DNA was available from the father. To test if this variant had arisen *de novo* on the maternal allele, a search for neutral heterozygous variants 5 kb upstream and downstream of exon 12 was performed. Detection of such variants would have allowed allele-specific PCR, and a distinction as to whether the variant resided on the maternal or the paternal allele. However, no heterozygous SNP or private variant was detected in the 10-kb flanking exon 12. Interestingly, pathogenicity prediction of this sequence alteration varied depending on the program used. According to Mutation Taster (www.mutationtaster.org), this variant had a 0.981 probability of being disease-causing. In contrast, three other programs predicted that it was benign: [PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>, benign with a score of 0.005); MutPred (<http://mutpred.mutdb.org>, probability of being deleterious 0.235); and SNPs&Go (<http://snps-and-go.biocomp.unibo.it/cgi-bin/snps-and-go/runpred.cgi>, reliability index 1)].

A third variant was identified in patient A02, who presented with anal atresia with recto-urethral prostatic fistula, ventricular septal defect, subaortic stenosis and dysplastic kidney. This synonymous *FGFR2* exon 18 variant (c.C2717T, p.Phe689=) was assumed to have no effect. Hence, no further analyses of this variant were performed.

Direct sequencing also generated information concerning several SNPs (dbSNP136) in the investigated genes. For all genes, similar haplotype data were found in the European Population of the International HapMap Project, the CEPH (Centre d'Etude du Polymorphisme Humain) pedigrees and the PDR90 (The NIH Polymorphism Discovery Resource; 90 individual screenings) subset.

Discussion

WNT/FGF signaling pathways (Fig. 1) orchestrate correct patterning, cell specification and tissue differentiation during embryogenesis (19,31). Research has shown that disruption of this coordinated interplay can result in severe malformations in mice and humans (49,50), including urogenital and anorectal anomalies. The present study investigated selected candidate genes from these pathways, chosen on the basis of observations in mice and human cell lines and/or their involvement in diseases associated with ARMs. However, no potential causal variant for ARMs was detected in the genes encoding WNT3A, WNT5A, WNT11, DACT1, FGF10 and T protein in the present cohort.

In contrast, *FGFR2* analysis revealed the presence of novel heterozygous variations in three patients (Fig. 2). We initially considered the two exon 12 variants to be of potential causal relevance. Our rationale for this hypothesis was that as well as affecting all *FGFR2* isoforms, a mutation in this exon would affect a cytoplasmic part of the protein which has not yet been implicated in the various forms of autosomal dominant craniosynostosis syndrome. Moreover, the program Mutation Taster (51) predicted that the p.Ala461Val amino acid substitution was disease-causing. However, Thusberg *et al* (52) reported on the suboptimal performance of this program and in line with their findings

of the performance of mutation pathogenicity prediction methods, several other - more reliable - programs classified it as benign. Furthermore, the results of our mRNA experiments suggest that the p.Thr454= variant had no effect on correct splicing.

Despite these negative findings, the possibility remains that these nucleotide substitutions contribute to the ARM phenotype through as-yet-unknown mechanisms. As *FGF10* is expressed in the mesenchyme that lies adjacent to the urethral plate, a plausible hypothesis is that it is important in the regulation of endoderm and/or mesenchyme growth, and thus in proliferation-driven urogenital and anorectal development (37,38). Interestingly, ARM patient B10 and his mother - both of whom showed spina bifida occulta - carried the silent p.Thr454= variant. Severe spinal dysraphism has been observed in association with an *FGFR2* p.Ser351Cys mutation (53) and spina bifida occulta occurs in the mouse mutant *Brachyury curtailed* ($T^{c/+}$) (54). However, whereas $T^{c/+}$ mice are tailless, several of the *FGFR2* amino acid substitutions observed in patients with Beare-Stevenson (55), Crouzon and Pfeiffer syndromes (56) are associated with sacral appendage. These findings, together with the repeated observation of ARMs in mice (37,38) and patients with *FGFR2* defects (39-47), imply that this FGF signaling pathway is of crucial importance in normal caudal development, rendering the coincidental co-occurrence of these defects unlikely.

In summary, no significant association between ARMs and mutations in *WNT3A*, *WNT5A*, *WNT11*, *DACT1*, *FGF10*, *FGFR2* or the *T* gene was found in the present cohort. However, although our patient cohort was larger than those used in previous candidate gene studies of ARMs (34,57-59), the sample size may have been too small to detect rare causal mutational events. Furthermore, we cannot exclude the possibility that mutations in the promoter region, in as yet unknown regulatory sequences or in non-coding regions that are not detectable with the method applied were overlooked. Future studies should consider additional proteins of the WNT/FGF signaling pathways as possible candidates.

Acknowledgements

M.D., A.H., S.S.M., E.S., E.B., M.M.N., H.R. and M.L. are members of the 'Network for the Systematic Investigation of the Molecular Causes, Clinical Implications and Psychosocial Outcome of Congenital Uro-Rectal Malformations (CURE-Net)', which is supported by a research grant (01GM08107) from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF). S.S.M. is supported by a research grant from the Richard-Winter-Stiftung. G.D. and E.B. are supported by the BONFOR program of the University of Bonn, grant nos. O-149.0096 and O-149.0099, respectively. We thank all patients and family members for their cooperation, as well as the German Self-Help Organization for People with Anorectal Malformations (SoMA e.V.). We thank Pia Uerdingen for her excellent technical assistance and Dr Christine Schmael for her expert advice regarding the manuscript.

References

- Smith ED: Incidence, frequency of types and aetiology of anorectal malformations. *Birth Defects Orig Artic Ser* 24: 231-246, 1988.
- Cho S, Moore SP and Fangman T: One hundred three consecutive patients with anorectal malformations and their associated anomalies. *Arch Pediatr Adolesc Med* 155: 587-591, 2001.
- Cuschieri A; EUROCAT Working Group: Descriptive epidemiology of isolated anal anomalies: a survey of 4.6 million births in Europe. *Am J Med Genet* 103: 207-215, 2001.
- Levitt MA and Peña A: Anorectal malformations. *Orphanet J Rare Dis* 2: 33, 2007.
- Stoll C, Alembik Y, Dott B and Roth MP: Associated malformations in patients with anorectal anomalies. *Eur J Med Genet* 50: 281-290, 2007.
- Cuschieri A; EUROCAT Working Group: Anorectal anomalies associated with or as part of other anomalies. *Am J Med Genet* 110: 122-130, 2002.
- Acs N, Bánhidly F, Puhó EH and Czeizel AE: A possible association between maternal dyspepsia and congenital rectal/anal atresia/stenosis in their children: a population-based case-control study. *Acta Obstet Gynecol Scand* 88: 1017-1023, 2009.
- Lin S, Munsie JPW, Herdt-Losavio ML, Druschel CM, Campbell K, Browne ML, Romitti PA, Olney RS and Bell EM; National Birth Defects Prevention Study: Maternal asthma medication use and the risk of selected birth defects. *Pediatrics* 129: e317-e324, 2012.
- Van Rooij IA, Wijers CH, Rieu PN, Hendriks HS, Brouwers MM, Knoers NV, de Blaauw I and Roeleveld N: Maternal and paternal risk factors for anorectal malformations: a Dutch case-control study. *Birth Defects Res A Clin Mol Teratol* 88: 152-158, 2010.
- Hackshaw A, Rodeck C and Boniface S: Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. *Hum Reprod Update* 17: 589-604, 2011.
- Tinker SC, Reefhuis J, Dellinger AM and Jamieson DJ: Maternal injuries during the periconceptional period and the risk of birth defects, National Birth Defects Prevention Study, 1997-2005. *Paediatr Perinat Epidemiol* 25: 487-496, 2011.
- Zwink N, Jenetzky E and Brenner H: Parental risk factors and anorectal malformations: systematic review and meta-analysis. *Orphanet J Rare Dis* 6: 25, 2011.
- Solomon B; VACTERL/VATER Association. *Orphanet J Rare Dis* 6: 56, 2011.
- Mundt E and Bates MD: Genetics of Hirschsprung disease and anorectal malformations. *Semin Pediatr Surg* 19: 107-117, 2010.
- Belloni E, Martucciello G, Verderio D, Ponti E, Seri M, Jasonni V, Torre M, Ferrari M, Tsui LC and Scherer SW: Involvement of the *HLXB9* homeobox gene in Currarino syndrome. *Am J Hum Genet* 66: 312-319, 2000.
- Kohlhase J, Wischermann A, Reichenbach H, Froster U and Engel W: Mutations in the *SALL1* putative transcription factor gene cause Townes-Brocks syndrome. *Nat Genet* 18: 81-83, 1998.
- Kang S, Graham JM Jr, Olney AH and Biesecker LG: *GLI3* frameshift mutations cause autosomal dominant Pallister-Hall syndrome. *Nat Genet* 15: 266-268, 1997.
- Clevers H: Wnt/beta-catenin signaling in development and disease. *Cell* 127: 469-480, 2006.
- Dorey K and Amaya E: FGF signalling: diverse roles during early vertebrate embryogenesis. *Development* 137: 3731-3742, 2010.
- Zhang X, Ibrahim OA, Olsen SK, Umemori H, Mohammadi M and Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem* 281: 15694-15700, 2006.
- Van de Ven C, Bialecka M, Neijts R, Young T, Rowland JE, Stringer EJ, van Rooijen C, Meijlink F, Növoa A, Freund JN, et al: Concerted involvement of *Cdx/Hox* genes and Wnt signaling in morphogenesis of the caudal neural tube and cloacal derivatives from the posterior growth zone. *Development* 138: 3451-3462, 2011.
- Spence JR, Mayhew CN, Rankin SA, Kuhar MW, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF and Wells JM: Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. *Nature* 470: 105-109, 2011.

23. Nakata M, Takada Y, Hishiki T, Saito T, Terui K, Sato Y, Koseki H and Yoshida H: Induction of *Wnt5a*-expressing mesenchymal cells adjacent to the cloacal plate is an essential process for its proximodistal elongation and subsequent anorectal development. *Pediatr Res* 66: 149-154, 2009.
24. Tai CC, Sala FG, Ford HR, Wang KS, Li C, Minoo P, Grikscheit TC and Bellusci S: *Wnt5a* knock-out mouse as a new model of anorectal malformation. *J Surg Res* 156: 278-282, 2009.
25. Mehta V, Abler LL, Keil KP, Schmitz CT, Joshi PS and Vezina CM: Atlas of *Wnt* and *R-spondin* gene expression in the developing male mouse lower urogenital tract. *Dev Dyn* 240: 2548-2560, 2011.
26. Lako M, Strachan T, Bullen P, Wilson DI, Robson SC and Lindsay S: Isolation, characterisation and embryonic expression of *WNT11*, a gene which maps to 11q13.5 and has possible roles in the development of skeleton, kidney and lung. *Gene* 219: 101-110, 1998.
27. Lickert H, Kispert A, Kutsch S and Kemler R: Expression patterns of *Wnt* genes in mouse gut development. *Mech Dev* 105: 181-184, 2001.
28. Railo A, Nagy II, Kilpeläinen P and Vainio S: *Wnt-11* signaling leads to down-regulation of the *Wnt/β-catenin*, *JNK/AP-1* and *NF- B* pathways and promotes viability in the CHO-K1 cells. *Exp Cell Res* 314: 2389-2399, 2008.
29. Cheyette BN, Waxman JS, Miller JR, Takemaru K, Sheldahl LC, Khlebtsova N, Fox EP, Earnest T and Moon RT: Dapper, a Dishevelled-associated antagonist of *β-catenin* and *JNK* signaling, is required for notochord formation. *Dev Cell* 2: 449-461, 2002.
30. Wen J, Chiang YJ, Gao C, Xue H, Xu J, Ning Y, Hodes RJ, Gao X and Chen YG: Loss of *Dact1* disrupts planar cell polarity signaling by altering dishevelled activity and leads to posterior malformation in mice. *J Biol Chem* 285: 11023-11030, 2010.
31. Pownall ME and Isaacs HV: FGF signalling in vertebrate development. In: *Developmental Biology*, Book 2, Kessler DS (ed); Morgan & Claypool Life Sciences, CA, pp14-16 2010.
32. Harembak T, Tanaka Y, Hongo I, Yuge M and Okamoto H: Integration of multiple signal transducing pathways on *Fgf* response elements of the *Xenopus caudal* homologue *Xcad3*. *Development* 130: 4907-4917, 2003.
33. Yamaguchi TP, Takada S, Yoshikawa Y, Wu N and McMahon AP: *T* (brachyury) is a direct target of *Wnt3a* during paraxial mesoderm specification. *Genes Dev* 13: 3185-3190, 1999.
34. Papapetrou C, Drummond F, Reardon W, Winter R, Spitz L and Edwards YH: A genetic study of the human *T* gene and its exclusion as a major candidate gene for sacral agenesis with anorectal atresia. *J Med Genet* 36: 208-213, 1999.
35. Ghebranious N, Blank RD, Raggio CL, Staubli J, McPherson E, Ivacic L, Rasmussen K, Jacobsen FS, Faciszewski T, Burmester JK, *et al*: A missense *T* (*Brachyury*) mutation contributes to vertebral malformations. *J Bone Miner Res* 23: 1576-1583, 2008.
36. Bagai S, Rubio E, Cheng JF, Sweet R, Thomas R, Fuchs E, Grady R, Mitchell M and Bassuk JA: Fibroblast growth factor-10 is a mitogen for urothelial cells. *J Biol Chem* 277: 23828-23837, 2002.
37. Fairbanks TJ, De Langhe S, Sala FG, Warburton D, Anderson KD, Bellusci S and Burns RC: Fibroblast growth factor 10 (*Fgf10*) inactivation results in anorectal malformation in mice. *J Pediatr Surg* 39: 360-365, 2004.
38. Yucel S, Liu W, Cordero D, Donjacour A, Cunha G and Baskin LS: Anatomical studies of the fibroblast growth factor-10 mutant, *Sonic Hedge Hog* mutant and androgen receptor mutant mouse genital tubercle. *Adv Exp Med Biol* 545: 123-148, 2004.
39. Ohashi H, Nishimoto H, Nishimura J, Sato M, Imaizumi S, Aihara T and Fukushima Y: Anorectal anomaly in Pfeiffer syndrome. *Clin Dysmorphol* 2: 28-33, 1993.
40. Park WJ, Meyers GA, Li X, Theda C, Day D, Orlow SJ, Jones MC and Jabs EW: Novel *FGFR2* mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. *Hum Mol Genet* 4: 1229-1233, 1995.
41. Park WJ, Theda C, Maestri NE, Meyers GA, Fryburg JS, Dufresne C, Cohen MM Jr and Jabs EW: Analysis of phenotypic features and *FGFR2* mutations in Apert syndrome. *Am J Hum Genet* 57: 321-328, 1995.
42. Pfeiffer RA, Rinnert S, Popp R and Röckelein G: Asymmetrical coronal synostosis, cutaneous syndactyly of the fingers and toes, and jejunal atresia in a male infant. *Am J Med Genet* 63: 175-176, 1996.
43. Przylepa KA, Paznekas W, Zhang M, Golabi M, Bias W, Bamshad MJ, Carey JC, Hall BD, Stevenson R, Orlow SJ, *et al*: Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. *Nat Genet* 13: 492-494, 1996.
44. LeHeup BP, Masutti JP, Droullé P and Tisserand J: The Antley-Bixler syndrome: report of two familial cases with severe renal and anal anomalies. *Eur J Pediatr* 154: 130-133, 1995.
45. Schaefer F, Anderson C, Can B and Say B: Novel mutation in the *FGFR2* gene at the same codon as the Crouzon syndrome mutations in a severe Pfeiffer syndrome type 2 case. *Am J Med Genet* 75: 252-255, 1998.
46. Křepelová A, Baxová A, Calda P, Plavka R and Kapras J: *FGFR2* gene mutation (Tyr375Cys) in a new case of Beare-Stevenson syndrome. *Am J Med Genet* 76: 362-364, 1998.
47. Kodaka T, Kanamori Y, Sugiyama M and Hashizume K: A case of acrocephalosyndactyly with low imperforate anus. *J Pediatr Surg* 39: E32-E34, 2004.
48. Shapiro MB and Senapathy P: RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. *Nucleic Acids Res* 15: 7155-7174, 1987.
49. Wilkie AO: Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations. *Cytokine Growth Factor Rev* 16: 187-203, 2005.
50. Shifley ET and Cole SE: The vertebrate segmentation clock and its role in skeletal birth defects. *Birth Defects Res C Embryo Today* 81: 121-133, 2007.
51. Schwarz JM, Rödelserperger C, Schuelke M and Seelow D: MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 7: 575-576, 2010.
52. Thusberg J, Olatubosun A, Vihinen M: Performance of mutation pathogenicity prediction methods on missense variants. *Hum Mutat* 32: 358-368, 2011.
53. Chun K, Siegel-Bartelt J, Chitayat D, Phillips J and Ray PN: *FGFR2* mutation associated with clinical manifestations consistent with Antley-Bixler syndrome. *Am J Med Genet* 77: 219-224, 1998.
54. Park CHT, Pruitt JH and Bennett D: A mouse model for neural tube defects: The curtailed (*T⁻*) mutation produces spina bifida occulta in *T⁺/+* animals and spina bifida with meningocele in *T⁻/t*. *Teratology* 39: 303-312, 1989.
55. McGaughan J, Sinnott S, Susman R, Buckley MF, Elakis G, Cox T and Roscioli T: A case of Beare-Stevenson syndrome with a broad spectrum of features and a review of the *FGFR2* Y375C mutation phenotype. *Clin Dysmorphol* 15: 89-93, 2006.
56. Shanske AL, Staffenberg D and Goodrich JT: Sacral appendage in a child with an *FGFR2* mutation: a report and review. *Am J Med Genet A* 146A: 2172-2175, 2008.
57. Seri M, Martucciello G, Paleari L, Bolino A, Priolo M, Salemi G, Forabosco P, Caroli F, Cusano R, Tocco T, *et al*: Exclusion of the *Sonic Hedgehog* gene as responsible for Currarino syndrome and anorectal malformations with sacral hypodevelopment. *Hum Genet* 104: 108-110, 1999.
58. Krüger V, Khoshvaghti M, Reutter H, Vogt H, Boemers TM and Ludwig M: Investigation of *FGF10* as a candidate gene in patients with anorectal malformations and exstrophy of the cloaca. *Pediatr Surg Int* 24: 893-897, 2008.
59. Agochukwu NB, Pineda-Alvarez DE, Keaton AA, Warren-Mora N, Raam MS, Kamat A, Chandrasekharappa SC and Solomon BD: Analysis of *FOXF1* and the *FOX* gene cluster in patients with VACTERL association. *Eur J Med Genet* 54: 323-328, 2011.
60. Catala M: Genetic control of caudal development. *Clin Genet* 61: 89-96, 2002.
61. Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, Vijayakumar S, Economides AN and Aaronson SA: Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. *Genes Dev* 24: 2517-2530, 2010.
62. Uysal-Onganer P and Kypta RM: *Wnt11* in 2011 - the regulation and function of a non-canonical Wnt. *Acta Physiol (Oxf)* 204: 52-64, 2012.